Cordlife Group Limited (SGX:P8A)

Market Cap	33.83M -32.3%
Revenue (ttm)	38.26M +17.3%
Net Income	-12.75M
EPS	-0.05
Shares Out	256.31M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	69,900
Open	0.1320
Previous Close	0.1320
Day's Range	0.1320 - 0.1320
52-Week Range	0.1050 - 0.2600
Beta	0.67
Analysts	n/a
Price Target	n/a
Earnings Date	Aug 12, 2026

About Cordlife Group

Cordlife Group Limited, an investment holding company, provides cord blood banking services in Singapore, Hong Kong, India, Malaysia, the Philippines, and internationally. It operates in two segments, Banking and Diagnostics. The Banking segment collects, processes, banks, and tests biological materials, such as cord blood, lining, and tissue samples. The Diagnostics segment offers diagnostic testing services, such as newborn genetic and metabolic screenings; pediatric vision and ear screenings; pediatric allergen test; and genetic talent test ...

• Industry: Medical - Diagnostics & Research
• Sector: Healthcare
• Founded: 2001
• Employees: 538
• Stock Exchange: Singapore Exchange
• Ticker Symbol: P8A

Financial Performance

In 2025, Cordlife Group's revenue was 38.85 million, an increase of 40.53% compared to the previous year's 27.65 million. Losses were -12.64 million, -33.06% less than in 2024.

Data Sources: S&P Global Market Intelligence and Financial Modeling Prep

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Financial Modeling Prep.

Last checked:

Aug 12, 2026

Data Sources Report a data error